1-4 of 4
Doug Sborov
Close
Sort by
Journal Articles

Gain1q in Myeloma Randomized Clinical Trials- How Is It Reported and How Does It Impact Outcomes: A Systematic Review

Karun Neupane, Gliceida Galarza Fortuna, Riyasha Dahal, Timothy M Schmidt, Rafael Fonseca, Doug Sborov, Meera Mohan, Hira Mian, Rajshekhar Chakraborty, Ghulam Rehman Mohyuddin
Journal: Blood
Blood (2023) 142 (Supplement 1): 3363.
https://doi.org/10.1182/blood-2023-180271
Published: 2023
Journal Articles

Prevalence of Exclusion Criteria in Multiple Myeloma Randomized Controlled Trials: A Systematic Review

Joshua White, Sara Zhukovsky, Edward R Scheffer Cliff, Rajshekhar Chakraborty, Luciano Costa, Oliver Van Oekelen, Doug Sborov, Ghulam Rehman Mohyuddin
Journal: Blood
Blood (2023) 142 (Supplement 1): 2402.
https://doi.org/10.1182/blood-2023-185175
Published: 2023
Journal Articles

Performance of Newer Staging Systems for Myeloma in a Contemporary, Large Cohort of Patients in the United States

Ghulam Rehman Mohyuddin, Samuel M Rubinstein, Shaji Kunnathu Kumar, S. Vincent Rajkumar, Rafael Fonseca, Nadine Abdallah, Greg Calip, Xiaoyan Wang, Christina Parrinello, Doug Sborov
Journal: Blood
Blood (2023) 142 (Supplement 1): 1068.
https://doi.org/10.1182/blood-2023-185136
Published: 2023
Journal Articles

Sonrotoclax (BGB-11417) in Combination with Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma with t(11;14): Safety, Efficacy, and Determination of Recommended Phase 2 Dose

Hang Quach, Doug Sborov, Dickran Kazandjian, Andrew Spencer, Michael Low, Susan Bal, Natalie S. Callander, Huan Cheng, Sheel Patel, Rocco J. Crescenzo, Amit Agarwal, Binod Dhakal
Journal: Blood
Blood (2023) 142 (Supplement 1): 1011.
https://doi.org/10.1182/blood-2023-178735
Published: 2023